Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.
Researchers from Capital Medical University have presented preclinical data for the novel PDZ-binding kinase (PBK) inhibitor, HI-TOPK-032, which is being developed for the treatment of cancer. The study aimed to assess the effects of the candidate on NK-92MI cell infiltration into ovarian tumors.
Iambic Therapeutics Inc. has disclosed quinazoline compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK2 and/or CDK4 and/or CDK6 inhibitors reported to be useful for the treatment of ovarian and breast cancer.
Lantern Pharma Inc. has generated a new class of highly specific and highly potent antibody-drug conjugates (ADCs) with a cryptophycin drug-payload, in collaboration with Bielefeld University.
Sutro Biopharma Inc. has described antibody-drug conjugates (ADCs) comprising a cytotoxic drug linked to an antibody or polypeptide residue through a linker reported to be useful for the diagnosis and treatment of cancer.
Medigene AG has selected initial clinical indications for its lead candidate, MDG-1015, specifically gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.
Second Affiliated Hospital of Wenzhou Medical University investigators have assessed the functions of FBXO28 on proliferation, migration and invasion in ovarian cancer.
About 75% of patients with ovarian cancer are diagnosed with advanced disease. It is hence of high importance to explore reliable biomarkers and their mechanisms during pathology. Growing evidence exists regarding long noncoding RNAs (lncRNAs) as regulatory factors in several cellular processes.
Accent Therapeutics Inc. has completed a $75 million series C financing to support progression of its lead programs through early clinical development.
